The data on long-term efficacy, safety and drug survival rates of conventional systemic therapeutics in pediatric psoriasis is lacking. The primary aim of this study is to investigate acitretin, methotrexate, cyclosporin efficacy, safety and drug survival rates in pediatric patients as well as predictors of drug survival. This is a multicenter study including 289 pediatric cases being treated with acitretin, methotrexate and cyclosporin in four academic referral centers. Efficacy, adverse events, reasons for discontinuation, 1, 2-and 3-year drug survival rates, and determinants of drug survival were analyzed. A 75% reduction of Psoriasis Area and Severity Index score or better response rate was obtained in 47.5%, 34.1% and 40% of the patients who were treated with acitretin, methotrexate and cyclosporin, respectively. One-year drug survival rates for acitretin, methotrexate and cyclosporin were 36.3%, 21.1% and 15.1%, respectively. The most significant determinant of drug survival, which diminished over time, was treatment response whereas arthritis, body mass index and sex had no influence. Although all three medications are effective and relatively safe in children, drug survival rates are low due to safety concerns at this age group. Effective disease control through their rational use can be expected to improve survival rates.
INTRODUCTION
Pediatric psoriasis is a relatively common disorder with a prevalence of 0.71%, representing nearly 4% of all dermatoses in patients younger than 16 years of age. 1, 2 Treating childhood psoriasis is a challenge. As controlled studies supporting a high level of evidence are lacking, currently available systemic treatment modalities are being used on the basis of studies showing their efficacy or clinical experience with them. 1, [3] [4] [5] [6] Likewise, long-term safety of therapeutic options in the pediatric population is unknown. Drug survival, which is time to termination of treatment modality, is an overall marker of performance of the agent used in real-life conditions. 7, 8 It gives information on efficacy, safety and adherence, all of which are critical parameters aiding the clinician in disease management. 9, 10 The data on drug survival of traditional and biologic agents in pediatric psoriasis is lacking. As pediatric patients may differ from adults, in terms of pharmacokinetics, drug metabolism/elimination, tolerance/ safety, impact of medication on growth and development, and influence on routine vaccination, data from adults cannot completely be extrapolated to childhood. 11, 12 The primary aim of this study was to investigate the drug survival rates of acitretin, methotrexate and cyclosporin in a pediatric psoriasis cohort. Response to treatment, adverse events (AE) and reasons for termination of each medication were analyzed. We also aimed to investigate predictors of poor drug survival. Accordingly, pediatric psoriasis cohort with 289 children, being followed up in four academic referral clinics were analyzed.
METHODS Setting
The psoriatic cohort consisted of patients being treated by each of the authors according to S3 guidelines on the management of psoriasis in specialized psoriasis clinics of university hospitals. 13 Psoriasis severity is determined at each visit through the Psoriasis Area and Severity Index (PASI) for all subtypes except for palmoplantar pustulosis which has been evaluated through the Physician's Global Assessment (PGA). Follow-up visits and laboratory monitoring are performed at least every 3 months (range, 2-12 weeks). Initial doses for acitretin, methotrexate and cyclosporin were 0.3 mg/kg per day, 0.3 mg/kg per week and 3 mg/kg per day, respectively. If sufficient response was not achieved, the doses were increased to 0.5 mg/kg per day, 0.7 mg/kg per week and 5 mg/kg per day, respectively.
Design
Patients with psoriasis under the age of 18 years, being followed up in psoriasis outpatient clinics and having at least one successive follow-up visit following initiation of acitretin, methotrexate or cyclosporin treatments in one of the study centers were eligible for enrollment. All treatment courses of the patients were evaluated. The study was approved by the institutional review board. In addition to demographic features, data on the following parameters were obtained:
Response to treatment, defined by: 0, no response or worsening; 1, 25% reduction of PASI (PASI-25); 2, PASI-50; 3, PASI-75; and 4, PASI-90.
3
Duration of response, defined by time to the loss of 50% of the PASI improvement. 4
Adverse events.
5
Reason for termination of the agent defined by: 0, primary lack of efficacy; 1, secondary loss of efficacy; 2, adverse event; 3, dissatisfaction/incompliance/lost to follow up; and 4, complete/near complete involution without AE.
Drug survival rate was estimated by identifying the percentage of patients using these medications 1, 2 and 3 years after commencement of therapy.
Statistics
Descriptive data are shown as n (%) for categorical variables and median (interquartile range) or mean AE standard deviation (range) for quantitative variables. Distribution of data was assessed using the Kolmogorov-Smirnov test. The v 2 -test was used for categorical variables and independent samples t-test or Mann-Whitney U-test for continuous variables according to distribution of the data. Kaplan-Meier survival analysis (with log-rank test) was used for univariate comparisons of censored data. Cox proportional hazard models were used for multivariate analysis.
Variables of the Cox regression model consisted of sex, age, body mass index, family history for psoriasis, arthritis, itching, present psoriasis form, duration of psoriasis and PASI response. Duration of psoriasis was excluded from analysis due to high correlation with other variables. The backward logistic regression strategy was used for regression. Analysis was performed with SPSS version 20 software (SPSS, Chicago, IL, USA). P < 0.05 was considered statistically significant.
RESULTS

Patient demographics
Two hundred and eighty-nine pediatric psoriasis patients, 171 females (59.2%) and 118 (40.8%) males with a median age of 11 years (range, 9-14), were included. Median follow-up period was 12 months (range, 5-24). Psoriatic arthritis was found in 5.2% of cases.
Treatment outcomes
Among 289 pediatric patients, acitretin, methotrexate and cyclosporin were used by 62 (21.5%), 88 (30.6%) and 82 (28.5%) cases, respectively. Response to these modalities are shown in Table 1 .
Mean duration of treatment (and range) was 9.16 AE 9.06 (1-55), 7.05 AE 6.3 (1-36) and 6.51 AE 5.08 months (1-24) for acitretin, methotrexate and cyclosporin, respectively.
AE
No severe AE were seen in any of the patients. Acitretin was well tolerated without causing AE in 70.7% of patients. Among AE, mucocutaneous, hyperlipidemia and gastrointestinal (nausea) AE were seen in 25.9%, 1.7% and 1.7% of patients, respectively.
Methotrexate was well tolerated by 90.8% of cases with no adverse events. Nausea and vomiting were the most common AE, followed by abnormal liver function tests, which were seen in 8% and 1.1% of patients, respectively.
Cyclosporin was used without AE in 77.5% of cases. Hyperlipidemia was seen in three (3.8%) patients and elevation in serum creatinine, gastrointestinal upset and cytopenia were each seen in one patient (1.3%).
Reasons for termination of treatment
Primary lack of efficacy or secondary loss of efficacy was found to be the most common cause of treatment termination for all medications (Table 2) . Overall, 28.4%, 22.9% and 31.7% of cases using acitretin, methotrexate and cyclosporin discontinued treatment due to inefficacy, respectively.
Drug survival rates
Mean survivals (and 95% CI) of acitretin, methotrexate and cyclosporin were 15.4 (10.1-20.8), 8.8 (6.7-10.8) and 7.3 months (5.8-8.7), respectively. One-, 2-and 3-year estimated survival rates of medications are shown in Table 3 . Kaplan-Meier drug survival analysis for each drug is shown in Figure 1 .
Responses of PASI-75 and PASI-90 were statistically significantly related to better survival for acitretin (P < 0.001 for all) and methotrexate (P = 0.001). However, the impact of good response to cyclosporin survival was found to be insignificant (P = 0.180).
When determinants of drug survival were analyzed, poor response to treatment, which is defined as PASI-50 response or less, and itching were found to increase discontinuation of acitretin 4.04 (range, 1.06-15.32) and 4.41 times (range, 1.20-16.26), respectively (P = 0.040 and P = 0.026). Poor response to treatment was also related to methotrexate discontinuation by a factor of 2.46 (range, 1.38-4.40) (P = 0.002) whereas cyclosporin drug survival was not influenced by any of the analyzed parameters. Other factors such as presence of arthritis, body mass index and sex had no influence on drug survival rates (data not shown).
DISCUSSION
Although pediatric psoriasis is a relatively common disease causing severe physical and psychosocial disability, treatment guidelines supported by studies providing a high class of evidence are lacking. Furthermore, long-term efficacy and safety data of systemic antipsoriatic agents in pediatric cases do not exist. 14, 15 We are the first to analyze the efficacy and found that 47.5% of 61 pediatric patients treated with acitretin achieved at least PASI-75 response (Table 1) . Although we cannot compare our data with the published work as acitretin data for pediatric psoriasis is limited to only two cases, we can conclude that acitretin is effective, providing PASI-50 response or more in 65.5% of patients. children with various forms of psoriasis treated by methotrexate. Our results were found to be similar to those of Geel et al. 17 As response to methotrexate is determined by various factors including the dose, route of administration, type of psoriasis and inherent differences of the patients, controlled studies are required to address the efficacy reliably. Nevertheless, including 23.5% of patients achieving PASI-50 response we may claim methotrexate to provide a PASI-50 response or more in 57.6% of patients and being an effective and cheap medication in treatment of pediatric cases deserving systemic therapy. Among 80 patients using cyclosporin, 40% achieved a PASI-75 response or more. Published work on outcomes of pediatric psoriasis cases using cyclosporin is limited to nine patients, mostly with generalized pustular psoriasis (n = 5).
Response was reported to range from 100% healing to no response. 16 Although we cannot compare our data with the published work, our response rate is lower than the reported cyclosporin efficacy in adults. This may be due to low bioavailability of cyclosporin in children which may be both due to poor absorption and also prehepatic metabolism. Consequently, higher doses of cyclosporin may be necessary in children. When we compare efficacy data of pediatric cases to our adult patients, PASI-75 responses or more obtained by acitretin, methotrexate and cyclosporin use were 45.6%, 64.2% and 81.3%, respectively (Dr Tulin Ergun, 2016, unpubl. data). This difference may be related either due to avoidance of high doses of these medications in children for safety concerns or different pharmacokinetics, which has been shown for cyclosporin. 19 In general, treatments were tolerated well in children. Acitretin was used free of AE in 70.7% of patients. Although mucocutaneous AE were common, hyperlipidemia was seen in 1.7% of cases whereas abnormal liver transaminases were not observed at all. Taken together, acitretin can be considered an effective and safe medication in the setting of good screening, optimal dosing and good monitoring conditions. 20, 21 Methotrexate was also well tolerated as 90.8% of cases used it without AE. Nausea and vomiting were the most common AE followed by abnormal liver function tests results which were seen in 8% and 1.1% of cases, respectively. When compared with the published work, methotrexate had a better safety profile in our hands. Severe nausea (20%), infections requiring antibiotics (20%) and tiredness (16%) were the main reported AE by Geel et al. 17 and nausea, vomiting and loss of appetite were seen in 37.5% of children treated by Kaur et al. 18 This difference may be explained by routine supplementation of folic acid in our patients, which has proven to decrease AE. Accordingly, methotrexate can be considered as a relatively safe and effective medication with predictable AE in children. In addition to good patient selection and careful baseline screening, close monitoring is also mandatory. Although precise conclusions cannot be made, folic acid supplementation may be helpful to decrease AE. 22 The safety profile of cyclosporin was acceptable as hyperlipidemia and elevation in serum creatinine developed in 3.8% and 1.3% of patients, respectively, whereas arterial hypertension did not occur. Considering this data, cyclosporin can also be considered for use in children unresponsive to and/or cannot tolerate other treatment options, under close monitoring.
In terms of safety, our pediatric cases were found to tolerate these medications better than our adult cases (Dr Tulin Ergun, 2016, unpubl. data). Hyperlipidemia and increased transaminases which are common dose-limiting adverse effects for acitretin were seen in 43.3%, and 8.5% of adult cases, whereas 1.7% and 0% of pediatric cases developed them, respectively. Methotrexate caused liver function abnormalities, gastrointestinal AE and cytopenia in 22%, 16.7% and 4.2% of adult cases, while only 1.1%, 8% and 0% of pediatric cases experienced them, respectively. Among the adult cases using cyclosporin, hyperlipidemia, abnormal serum creatinine levels and arterial hypertension were seen in 25.2%, 18.4% and 9.7% of the patients, respectively. However, these adverse effects were observed in only 3.8%, 1.3% and 0% of pediatric cases, respectively.
We analyzed the treatment duration and found it to be longest for acitretin, up to 55 months. Acitretin had the best 1-(36.3%), 2-(13.3%) and 3-year (13.3%) survival rates followed by methotrexate. Acitretin has major advantages for long-term use such as being the antipsoriatic agent not causing immunosuppression, not interfering with vaccination, ability for combination with phototherapy and no time or cumulative dose limitations on long-term basis as long as safety is guaranteed, all of which can explain the high survival rates. When we analyzed methotrexate survival, 1-, 2-and 3-year survival rates were 21.1%, 6.8% and 3.4%, respectively. As expected, drug survival rates were lowest for cyclosporin, the use of which has been limited to 1 year by current guidelines. One-, 2-and 3-year survival rates for cyclosporin were 15.1%, 6.5% and 0%, respectively. This may be explained by a tendency to terminate treatment in children once satisfactory response is achieved for safety concerns.
We investigated predictors of drug survival. As one can expect, PASI-75 response or more was the significant determinant for higher drug survival rate. Interestingly, itching tended to decrease drug survival for acitretin 4.4 times, which points out the importance of symptom control in management of disease. Unexpectedly, we found presence of arthritis, body mass index and sex to have no influence on drug survival.
One of the important findings of this study is high rates of loss of response as a factor for drug discontinuation. Up to 16.5% of patients terminated treatment because of secondary loss of efficacy which emphasizes the importance of efficacy assessment of any given method on a long-term basis. Another important finding is high incompliance/dissatisfaction rates which led to up to 32.9% of cases to terminate treatment. This finding highlights the importance of informing the patient precisely on risks and benefits of treatment and also providing psychosocial support to improve compliance. 23 There are several limitations of this study. One is lack of stratification of patients according to disease severity. Another is lack of information on the causes of dissatisfaction and incompliance. Nevertheless, the current study includes the highest number of patients reported to date for each of the medications and provides valuable information on long-term efficacy, safety and adherence to treatment in real-life conditions. It also provides data which can be used to estimate medical care costs. Although etanercept and recently adalimumab are approved biologic agents for pediatric psoriasis, new biologic agents are under investigation, and time to termination of conventional medications and switch to biologics, which are much more expensive, is important for estimating overall cost of the health care. 4, 24, 25 In conclusion, acitretin, methotrexate and cyclosporin are all found to be effective and well tolerated in children with psoriasis in real-life conditions. In spite of an increasing number of treatment alternatives including biologics, conventional agents remain to be important options in pediatric psoriasis. Improving their efficacy through optimal dosing, effective control of symptoms like itching and taking measures to enhance compliance are the main factors for better drug survival.
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